Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Rating of "Moderate Buy" from Analysts

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the five research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $9.00.

A number of equities research analysts have issued reports on the stock. HC Wainwright reiterated a "buy" rating and set a $5.00 target price on shares of Pyxis Oncology in a report on Monday, May 19th. Royal Bank Of Canada reiterated an "outperform" rating and issued a $8.00 target price on shares of Pyxis Oncology in a report on Wednesday, March 19th.

Hedge Funds Weigh In On Pyxis Oncology

Several large investors have recently bought and sold shares of the stock. Millennium Management LLC boosted its position in shares of Pyxis Oncology by 53.8% in the 4th quarter. Millennium Management LLC now owns 2,980,906 shares of the company's stock valued at $4,650,000 after purchasing an additional 1,043,228 shares during the period. Jane Street Group LLC raised its position in Pyxis Oncology by 36.6% in the 4th quarter. Jane Street Group LLC now owns 67,686 shares of the company's stock valued at $106,000 after purchasing an additional 18,128 shares during the last quarter. ProShare Advisors LLC purchased a new position in Pyxis Oncology during the 4th quarter worth $26,000. Ameriprise Financial Inc. purchased a new position in Pyxis Oncology during the 4th quarter worth $35,000. Finally, American Century Companies Inc. increased its stake in Pyxis Oncology by 88.1% in the fourth quarter. American Century Companies Inc. now owns 299,937 shares of the company's stock valued at $468,000 after purchasing an additional 140,498 shares during the period. Institutional investors and hedge funds own 39.09% of the company's stock.

Pyxis Oncology Stock Performance

Shares of NASDAQ PYXS traded down $0.03 during trading on Friday, reaching $1.16. The stock had a trading volume of 715,048 shares, compared to its average volume of 729,937. The business's 50-day moving average price is $1.19 and its 200-day moving average price is $1.24. Pyxis Oncology has a fifty-two week low of $0.83 and a fifty-two week high of $5.39. The company has a market cap of $71.86 million, a P/E ratio of -0.73 and a beta of 1.13.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.06). Analysts forecast that Pyxis Oncology will post -1.04 EPS for the current fiscal year.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.